NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX) announced the completion of its global offering that raised approximately $100 million in gross proceeds.

The biotechnology company issued 2,218,467 ordinary shares and 345,099 pre-funded warrants. The offering included 225,373 ordinary shares in the form of American Depositary Shares and 33,805 additional ADSs following the full exercise of underwriters' over-allotment option.

The subscription price was set at €33.60 per ordinary share, equivalent to $38.98 per ADS based on a May 20, 2026 exchange rate. This represented a 14.92% discount to the volume weighted average price over the three trading sessions preceding the pricing.

The company plans to allocate the net proceeds as follows: less than 10% for JNJ-1900 (NBTXR3) development, 50-60% for Nanoprimer and other platforms, and 30-40% for general corporate purposes.

NANOBIOTIX stated the proceeds, combined with existing cash and cash equivalents, will fund operations into 2029 based on current cash burn projections.

Jefferies, TD Cowen and Stifel served as global coordinators and joint bookrunners for the offering. The stabilizing agent reported no stabilization activities were conducted during the offering period.

The ADSs trade on the Nasdaq Global Select Market under "NBTX" and ordinary shares are listed on Euronext Paris under "NANO." The offering was conducted under an effective shelf registration statement filed with the Securities and Exchange Commission.

NANOBIOTIX is a late-clinical stage biotechnology company developing physics-based cancer treatments. Founded in 2003 and headquartered in Paris, the company has been listed on Euronext since 2012 and Nasdaq since December 2020.